“Preconditioning” with latrepirdine, an adenosine 5′-monophosphate-activated protein kinase activator, delays amyotrophic lateral sclerosis progression in SOD1G93A mice

Abstract

Adenosine 5′-monophosphate-activated protein kinase (AMPK) is a master regulator of energy balance. As energy imbalance is documented as a key pathologic feature of amyotrophic lateral sclerosis (ALS), we investigated AMPK as a pharmacologic target in SOD1G93A mice. We noted a strong activation of AMPK in lumbar spinal cords of SOD1G93A mice. Pharmacologic activation of AMPK has shown protective effects in neuronal “preconditioning” models. We tested the hypothesis that “preconditioning” with a small molecule activator of AMPK, latrepirdine, exerts beneficial effects on disease progression. SOD1G93A mice (n = 24 animals per group; sex and litter matched) were treated with latrepirdine (1 μg/kg, intraperitoneal) or vehicle from postnatal day 70 to 120. Treatment with latrepirdine increased AMPK activity in primary mouse motor neuron cultures and in SOD1G93A lumbar spinal cords. Mice “preconditioned” with latrepirdine showed a delayed symptom onset and a significant increase in life span (p < 0.01). Our study suggests that “preconditioning” with latrepirdine may represent a possible therapeutic strategy for individuals harboring ALS-associated gene mutations who are at risk for developing ALS.